Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TNF | P01375 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21326445 | 0.85 | KDM4E (0.44) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL28548830 | 0.85 | RAB9A (0.45) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL20839867 | 0.84 | HDAC1 (0.43) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL9952440 | 0.84 | KDM4E (0.42) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL2275524 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL21984979 | 0.83 | LMNA (0.51) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL9951657 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL2275450 | 0.83 | LMNA (0.51) | SMN1; SMN2MAPTKMT2ALMNAGAA | |
| SCHEMBL20554157 | 0.82 | NR1H4 (0.39) | LMNAGAANR1H4 | |
| SCHEMBL21262000 | 0.80 | LMNA (0.48) | SMN1; SMN2MAPTKMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| CN-110818704-B | Spiro bridged ring compounds, pharmaceutical compositions thereof and uses thereof | 广州市恒诺康医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-03-18 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| CN-110818704-A | Spiro-bridged ring compounds, pharmaceutical compositions thereof and uses thereof | 广州市恒诺康医药科技有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | NR1H4, FXR1, FXR2 | SMN1; SMN2 4820/4885MAPT 3342/4885KMT2A 3452/4885 |
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | NR1H4, FXR1, GPBAR1 | SMN1; SMN2 4837/4885MAPT 3695/4885KMT2A 3129/4885 |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | NR1H4, FXR1, FXR2 | SMN1; SMN2 4820/4885MAPT 3342/4885KMT2A 3452/4885 |
| US-20210079006-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | NR1H4, FXR1, FXR2 | SMN1; SMN2 4820/4885MAPT 3342/4885KMT2A 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.